Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
What would move this position is: a randomised, placebo-controlled trial in a defined population with an objective primary endpoint, a pre-registered protocol, and pharmacovigilance over a clinically meaningful duration
TB-500's parent Thymosin -4 has been characterised across actin-cytoskeleton dynamics, cell migration, cardiac progenitor mobilisation, and corneal wound-healing in foundational and contemporary research (PMID 11579089, PMID 15565145, PMID 11950239)
These effects occurred more frequently at higher doses and were generally consistent with the known side effect profile of incretin-based therapies
To understand the underlying mechanisms, inhibitors targeting the Notch pathway (DAPT) and NF-B pathway (BMS) were also applied to HUVEC and murine CLI models
US$ 28.50
US$ 23.06
US$ 22.58
US$ 28.48
US$ 28.46
US$ 28.40
US$ 27.42
US$ 27.89
US$ 28.56
US$ 29.24
US$ 27.35
US$ 28.27
